These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 32559817)

  • 1. Real-world outcomes of advanced melanoma patients not represented in phase III trials.
    van Zeijl MCT; Ismail RK; de Wreede LC; van den Eertwegh AJM; de Boer A; van Dartel M; Hilarius DL; Aarts MJB; van den Berkmortel FWPJ; Boers-Sonderen MJ; de Groot JB; Hospers GAP; Kapiteijn E; Piersma D; van Rijn RS; Suijkerbuijk KPM; Ten Tije AJ; van der Veldt AAM; Vreugdenhil G; Haanen JBAG; Wouters MWJM
    Int J Cancer; 2020 Dec; 147(12):3461-3470. PubMed ID: 32559817
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world Outcomes of First-line Anti-PD-1 Therapy for Advanced Melanoma: A Nationwide Population-based Study.
    van Zeijl MCT; Haanen JBAG; Wouters MWJM; de Wreede LC; Jochems A; Aarts MJB; van den Berkmortel FWPJ; de Groot JWB; Hospers GAP; Kapiteijn EW; Piersma D; van Rijn RS; Suijkerbuijk KPM; Ten Tije AJ; van der Veldt AAM; Vreugdenhil G; van der Hoeven KJM; van den Eertwegh AJM
    J Immunother; 2020 Oct; 43(8):256-264. PubMed ID: 32804914
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world experience with pembrolizumab in patients with advanced melanoma: A large retrospective observational study.
    Liu FX; Ou W; Diede SJ; Whitman ED
    Medicine (Baltimore); 2019 Jul; 98(30):e16542. PubMed ID: 31348273
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modeled Prognostic Subgroups for Survival and Treatment Outcomes in BRAF V600-Mutated Metastatic Melanoma: Pooled Analysis of 4 Randomized Clinical Trials.
    Hauschild A; Larkin J; Ribas A; Dréno B; Flaherty KT; Ascierto PA; Lewis KD; McKenna E; Zhu Q; Mun Y; McArthur GA
    JAMA Oncol; 2018 Oct; 4(10):1382-1388. PubMed ID: 30073321
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pembrolizumab Utilization and Outcomes for Advanced Melanoma in US Community Oncology Practices.
    Cowey CL; Liu FX; Black-Shinn J; Stevinson K; Boyd M; Frytak JR; Ebbinghaus SW
    J Immunother; 2018; 41(2):86-95. PubMed ID: 29252916
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy, safety and factors associated with disease progression in patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma: An open label, non-randomized, phase IIIb study of trametinib in combination with dabrafenib.
    Saiag P; Robert C; Grob JJ; Mortier L; Dereure O; Lebbe C; Mansard S; Grange F; Neidhardt EM; Lesimple T; Machet L; Bedane C; Maillard H; Dalac-Rat S; Nardin C; Szenik A; Denden A; Dutriaux C
    Eur J Cancer; 2021 Sep; 154():57-65. PubMed ID: 34243078
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes of patients with solid tumour malignancies treated with first-line immuno-oncology agents who do not meet eligibility criteria for clinical trials.
    Gan CL; Stukalin I; Meyers DE; Dudani S; Grosjean HAI; Dolter S; Ewanchuk BW; Goutam S; Sander M; Wells C; Pabani A; Cheng T; Monzon J; Morris D; Basappa NS; Pal SK; Wood LA; Donskov F; Choueiri TK; Heng DYC
    Eur J Cancer; 2021 Jul; 151():115-125. PubMed ID: 33975059
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The combination of stereotactic radiosurgery with immune checkpoint inhibition or targeted therapy in melanoma patients with brain metastases: a retrospective study.
    Martins F; Schiappacasse L; Levivier M; Tuleasca C; Cuendet MA; Aedo-Lopez V; Gautron Moura B; Homicsko K; Bettini A; Berthod G; Gérard CL; Wicky A; Bourhis J; Michielin O
    J Neurooncol; 2020 Jan; 146(1):181-193. PubMed ID: 31836957
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nivolumab for advanced melanoma: pretreatment prognostic factors and early outcome markers during therapy.
    Nakamura Y; Kitano S; Takahashi A; Tsutsumida A; Namikawa K; Tanese K; Abe T; Funakoshi T; Yamamoto N; Amagai M; Yamazaki N
    Oncotarget; 2016 Nov; 7(47):77404-77415. PubMed ID: 27764805
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical outcomes of adjuvant nivolumab in resected stage III melanoma: comparison of CheckMate 238 trial and real-world data.
    Moser JC; Bhatia S; Amin A; Pavlick AC; Betts KA; Du EX; Poretta T; Shelley K; Srinivasan S; Sakkal LA; Palaia J; Lobo M; Pe Benito M; Linton JA; Chen Y; Xu C; Yin L; Sundar M; Weber J
    Cancer Immunol Immunother; 2024 May; 73(7):116. PubMed ID: 38713408
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of Performance Status With Survival in Patients With Advanced Non-Small Cell Lung Cancer Treated With Pembrolizumab Monotherapy.
    Sehgal K; Gill RR; Widick P; Bindal P; McDonald DC; Shea M; Rangachari D; Costa DB
    JAMA Netw Open; 2021 Feb; 4(2):e2037120. PubMed ID: 33570575
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world survival of patients with advanced BRAF V600 mutated melanoma treated with front-line BRAF/MEK inhibitors, anti-PD-1 antibodies, or nivolumab/ipilimumab.
    Moser JC; Chen D; Hu-Lieskovan S; Grossmann KF; Patel S; Colonna SV; Ying J; Hyngstrom JR
    Cancer Med; 2019 Dec; 8(18):7637-7643. PubMed ID: 31677253
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic factors in metastatic melanoma: a pooled analysis of Eastern Cooperative Oncology Group trials.
    Manola J; Atkins M; Ibrahim J; Kirkwood J
    J Clin Oncol; 2000 Nov; 18(22):3782-93. PubMed ID: 11078491
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Representativeness of Phase III Trial for Osimertinib in Pretreated Advanced EGFR-Mutated Non-small-cell Lung Cancer Patients and Treatment Outcomes in Clinical Practice.
    Lin L; Smit EF; de Langen AJ; van Balen DEM; Beijnen JH; Huitema ADR
    Target Oncol; 2022 Jan; 17(1):53-59. PubMed ID: 34894319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006).
    Schachter J; Ribas A; Long GV; Arance A; Grob JJ; Mortier L; Daud A; Carlino MS; McNeil C; Lotem M; Larkin J; Lorigan P; Neyns B; Blank C; Petrella TM; Hamid O; Zhou H; Ebbinghaus S; Ibrahim N; Robert C
    Lancet; 2017 Oct; 390(10105):1853-1862. PubMed ID: 28822576
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vemurafenib in BRAF-mutant metastatic melanoma patients in real-world clinical practice: prognostic factors associated with clinical outcomes.
    Schouwenburg MG; Jochems A; Leeneman B; Franken MG; van den Eertwegh AJM; Haanen JBAG; van Zeijl MCT; Aarts MJ; van Akkooi ACJ; van den Berkmortel FWPJ; Blokx WAM; de Groot JWB; Hospers GAP; Kapiteijn E; Koornstra RH; Kruit WH; Louwman MWJ; Piersma D; van Rijn RS; Suijkerbuijk KPM; Ten Tije AJ; Vreugdenhil G; Wouters MWJM; van der Hoeven JJM
    Melanoma Res; 2018 Aug; 28(4):326-332. PubMed ID: 29750749
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic score for patients with advanced melanoma treated with ipilimumab.
    Diem S; Kasenda B; Martin-Liberal J; Lee A; Chauhan D; Gore M; Larkin J
    Eur J Cancer; 2015 Dec; 51(18):2785-91. PubMed ID: 26597444
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic factors for overall survival after radiosurgery for brain metastases from melanoma.
    Marcus DM; Lowe M; Khan MK; Lawson DH; Crocker IR; Shelton JW; Melton A; Maynard N; Delman KA; Carlson GW; Rizzo M
    Am J Clin Oncol; 2014 Dec; 37(6):580-4. PubMed ID: 23428955
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pembrolizumab for advanced nonsmall cell lung cancer: Efficacy and safety in everyday clinical practice.
    Ksienski D; Wai ES; Croteau N; Freeman AT; Chan A; Fiorino L; Brooks EG; Poonja Z; Fenton D; Geller G; Irons S; Lesperance M
    Lung Cancer; 2019 Jul; 133():110-116. PubMed ID: 31200816
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blood Predictive Biomarkers for Nivolumab in Advanced Melanoma.
    Chasseuil E; Saint-Jean M; Chasseuil H; Peuvrel L; Quéreux G; Nguyen JM; Gaultier A; Varey E; Khammari A; Dréno B
    Acta Derm Venereol; 2018 Apr; 98(4):406-410. PubMed ID: 29327065
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.